S309: SUSTAINED INHIBITION OF PLATELET ACTIVITY AND THROMBOSIS VIA IV AND ORAL ADMINISTRATION OF CS585
Main Authors: | Sylviane Lambert, Andrew Rickenberg, Bjorn Dahlof, Niklas Bergh, Michael Holinstat |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-08-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000968148.24216.e0 |
Similar Items
-
S298: CS585 IS A FIRST-IN-CLASS COMPOUND TARGETING THE IP RECEPTOR FOR PREVENTION OF THROMBOSIS WITHOUT INCREASED RISK OF BLEEDING
by: S. Lambert, et al.
Published: (2022-06-01) -
CS1, a controlled‐release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial
by: Raymond L. Benza, et al.
Published: (2024-01-01) -
423 An omega-6-derived eicosanoid negatively regulates platelet reactivity of cardiovascular patients at increased risk for thrombosis
by: Adriana Yamaguchi, et al.
Published: (2023-04-01) -
Edição de Julho 2012, vol. 99 (1), págs. 576-585 Issue of July 2012, vol. 99 (1), pp. 576-585
Published: (2013-03-01) -
The emerging role of oxylipins in thrombosis and diabetes
by: Benjamin Eric Tourdot, et al.
Published: (2014-01-01)